Predilife (ALPRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Predilife (ALPRE) has a cash flow conversion efficiency ratio of 0.219x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.28 Million ≈ $-1.49 Million USD) by net assets (€-5.82 Million ≈ $-6.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Predilife - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Predilife's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Predilife (ALPRE) total liabilities for a breakdown of total debt and financial obligations.
Predilife Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Predilife ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magna Terra Minerals Inc
V:MTT
|
-0.706x |
|
AIR INDUSTRIES GR.DL-001
F:YH1
|
N/A |
|
Sarama Resources Ltd
AU:SRR
|
1.779x |
|
Tecom Co Ltd
TW:2321
|
-0.015x |
|
Multi Prima Sejahtera Tbk
JK:LPIN
|
-0.008x |
|
Desenio Group AB
ST:DSNO
|
0.087x |
|
TEAM PLC
F:1WQ
|
N/A |
|
IDT Australia Ltd
AU:IDT
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Predilife (2016–2024)
The table below shows the annual cash flow conversion efficiency of Predilife from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see ALPRE market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-4.27 Million ≈ $-4.99 Million |
€-3.72 Million ≈ $-4.35 Million |
0.872x | +110.59% |
| 2023-12-31 | €513.52K ≈ $600.36K |
€-4.23 Million ≈ $-4.94 Million |
-8.236x | -1502.63% |
| 2022-12-31 | €-5.22 Million ≈ $-6.10 Million |
€-3.07 Million ≈ $-3.58 Million |
0.587x | -75.98% |
| 2021-12-31 | €-1.57 Million ≈ $-1.83 Million |
€-3.83 Million ≈ $-4.47 Million |
2.445x | +183.67% |
| 2020-12-31 | €721.69K ≈ $843.73K |
€-2.11 Million ≈ $-2.47 Million |
-2.922x | -193.26% |
| 2019-12-31 | €-764.29K ≈ $-893.53K |
€-2.39 Million ≈ $-2.80 Million |
3.133x | -97.90% |
| 2018-12-31 | €-12.10K ≈ $-14.15K |
€-1.81 Million ≈ $-2.11 Million |
149.479x | +12560.50% |
| 2017-12-31 | €-1.29 Million ≈ $-1.51 Million |
€-1.53 Million ≈ $-1.78 Million |
1.181x | +131.59% |
| 2016-12-31 | €362.63K ≈ $423.95K |
€-1.36 Million ≈ $-1.58 Million |
-3.737x | -- |
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer pred… Read more